X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
asunaprevir (284) 284
daclatasvir (267) 267
index medicus (239) 239
hepatitis c virus (210) 210
hepatitis c (202) 202
humans (197) 197
ribavirin (148) 148
gastroenterology & hepatology (140) 140
hepatitis c, chronic - drug therapy (132) 132
interferon (118) 118
hepatitis (114) 114
antiviral agents - therapeutic use (108) 108
hepacivirus - genetics (108) 108
genotype (107) 107
sofosbuvir (103) 103
drug therapy, combination (100) 100
male (99) 99
daclatasvir plus asunaprevir (94) 94
hepacivirus - drug effects (91) 91
female (90) 90
middle aged (89) 89
aged (82) 82
therapy (80) 80
hcv (79) 79
antiviral agents (77) 77
health aspects (76) 76
hepatitis c, chronic - virology (69) 69
imidazoles - therapeutic use (64) 64
infection (62) 62
pharmacology & pharmacy (62) 62
antiviral agents - adverse effects (61) 61
antiviral agents - administration & dosage (59) 59
liver (59) 59
treatment outcome (59) 59
genetic aspects (58) 58
adult (56) 56
analysis (54) 54
isoquinolines - therapeutic use (53) 53
patients (53) 53
sulfonamides - therapeutic use (53) 53
care and treatment (52) 52
imidazoles - administration & dosage (50) 50
chronic hepatitis c (49) 49
ledipasvir (49) 49
safety (49) 49
virus-infection (49) 49
cirrhosis (48) 48
genotypes (48) 48
liver cirrhosis (46) 46
direct-acting antivirals (45) 45
sulfonamides - administration & dosage (44) 44
sustained virological response (44) 44
isoquinolines - administration & dosage (43) 43
sustained virologic response (43) 43
virology (43) 43
genotype 1b (42) 42
hepatitis c - drug therapy (42) 42
treatment-naive patients (42) 42
efficacy (41) 41
genotype & phenotype (41) 41
telaprevir (41) 41
biological response modifiers (40) 40
genotype 1 infection (40) 40
viral nonstructural proteins - genetics (39) 39
hepatology (38) 38
infections (38) 38
treatment-naive (38) 38
ns5a inhibitor (37) 37
plus asunaprevir (37) 37
viruses (37) 37
aged, 80 and over (36) 36
medical research (35) 35
protease inhibitor (35) 35
protease inhibitors (35) 35
virus diseases (35) 35
imidazoles - adverse effects (34) 34
infectious diseases (34) 34
japanese patients (34) 34
medicine & public health (34) 34
medicine, experimental (34) 34
simeprevir (34) 34
antiviral agents - pharmacology (32) 32
hepatitis-c virus (32) 32
drug resistance, viral (31) 31
drug therapy (30) 30
fibrosis (30) 30
hemodialysis (30) 30
pegylated interferon (30) 30
gastroenterology (29) 29
isoquinolines - adverse effects (29) 29
sulfonamides - adverse effects (29) 29
viral nonstructural proteins - antagonists & inhibitors (29) 29
in-vitro (28) 28
ribavirin - therapeutic use (28) 28
combination (27) 27
drug resistance, viral - genetics (27) 27
japan (27) 27
proteases (27) 27
treatment failure (26) 26
chronic infection (25) 25
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Comparative Effectiveness Research, ISSN 2042-6305, 2018, Volume 7, Issue 8, pp. 785 - 795
Aim: To evaluate the cost-effectiveness of the novel all-oral direct-acting antiviral regimen daclatasvir + asunaprevir (DUAL), versus interferon-based... 
cost-effectiveness | daclatasvir + asunaprevir | hepatitis C | daclatasvir plus asunaprevir | VIRUS-INFECTION | TELAPREVIR | MANAGEMENT | REGIMENS | SUSTAINED VIROLOGICAL RESPONSE | GENOTYPES | DIFFICULT | PLUS ASUNAPREVIR | HEALTH CARE SCIENCES & SERVICES | HCV | TREATMENT-NAIVE PATIENTS
Journal Article
Hepatitis Monthly, ISSN 1735-143X, 09/2016, Volume 16, Issue 9, p. e41077
Context: Direct acting antivirals (DAAs) have recently emerged as a promising therapeutic regimen for the treatment of hepatitis C virus (HCV) infection, which... 
Daclatasvir | Therapy | Asunaprevir | Hepatitis C | Sofosbuvir | Meta-analysis | Meta-Analysis | RANDOMIZED-TRIAL | SUSTAINED VIROLOGICAL RESPONSE | PROTEASE INHIBITOR | NS5A INHIBITOR | TREATMENT OPTIONS | PLUS ASUNAPREVIR | NULL RESPONDERS | GASTROENTEROLOGY & HEPATOLOGY | ADVANCED LIVER-DISEASE | TREATMENT-NAIVE PATIENTS | GENOTYPE 1B INFECTION
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2012, Volume 58, Issue 4, pp. 646 - 654
Journal Article
World Journal of Gastroenterology, ISSN 1007-9327, 03/2018, Volume 24, Issue 12, pp. 1361 - 1372
AIM To assess daclatasvir plus asunaprevir (DUAL) in treatment-naive patients from mainland China, Russia and South Korea with hepatitis C virus (HCV) genotype... 
Direct-acting antiviral | Liver disease | DACLATASVIR/ASUNAPREVIR | RIBAVIRIN | NS3 | Genotype 1b | Daclatasvir | Chronic hepatitis C | NS5A | Asunaprevir | INHIBITOR | GASTROENTEROLOGY & HEPATOLOGY | EPIDEMIOLOGY | Randomized Clinical Trial
Journal Article
Gut and Liver, ISSN 1976-2283, 01/2018, Volume 12, Issue 1, pp. 86 - 93
Background/Aims: Although daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged >= 75 years were... 
Daclatasvir | Asunaprevir | Hepacivirus | Genotype 1b | RESISTANCE-ASSOCIATED VARIANTS | CHRONIC HEPATITIS-C | DACLATASVIR/ASUNAPREVIR | RIBAVIRIN | PLUS ASUNAPREVIR | THERAPY | JAPAN | HEMODIALYSIS | HCV GENOTYPE-1B | GASTROENTEROLOGY & HEPATOLOGY | GENOTYPE 1B INFECTION | Original | 내과학
Journal Article
Journal Article
Clinical Microbiology Reviews, ISSN 0893-8512, 07/2016, Volume 29, Issue 3, pp. 695 - 747
Journal Article
Journal Article
Journal of virology, ISSN 0022-538X, 01/2019, Volume 93, Issue 1
Influenza A virus (IAV) remains a global health concern despite the availability of a seasonal vaccine. It is difficult to predict which strains will circulate... 
influenza vaccines | virus engineering | biotechnology | ASUNAPREVIR | VIROLOGY | SAFETY | INFECTION | CORRELATE
Journal Article
Gut and Liver, ISSN 1976-2283, 2018, Volume 12, Issue 3, p. 324
Background/Aims: The treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C... 
Daclatasvir | Fibrosis | Asunaprevir | Hepatitis C | Genotype 1b
Journal Article
Gut and Liver, ISSN 1976-2283, 2018, Volume 12, Issue 3, p. 324
Background/Aims: The treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C... 
Daclatasvir | Fibrosis | Asunaprevir | Hepatitis C | Genotype 1b
Journal Article
Gut and Liver, ISSN 1976-2283, 2018, Volume 12, Issue 3, p. 324
Background/Aims: The treatment with daclatasvir plus asu-naprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis... 
Daclatasvir | Fibrosis | Asunaprevir | Hepatitis C | Genotype 1b
Journal Article
Gut and Liver, ISSN 1976-2283, 2018, Volume 12, Issue 3, p. 324
Background/Aims: The treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C... 
Daclatasvir | Fibrosis | Asunaprevir | Hepatitis C | Genotype 1b
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 04/2019, Volume 59, Issue 4, pp. 557 - 565
Journal Article